UNSPSC 51282604: Cefoselis

This classification denotes a cephalosporin antibiotic with the molecular formula C19H22N8O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0B50MLU3H1, chemically known as (-)-5-amino-2-(((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-(2-hydroxyethyl)pyrazolium hydroxide, inner salt, 7,2-(z)-(o-methyloxime). but generally known as cefoselis, which bears US NIH Compound Identifier 9589475.

UNSPSC 51282604 Cefoselis, a Commodity code, does not reflect the actual scope of state and local procurement activity tagged under it. The recent opportunities records show this code applied to acquisitions of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and emergency medical supplies — none of which are cefoselis (a fourth-generation cephalosporin antibiotic). State and local governments appear to use this code as a catch-all pharmaceutical classification, but the code shows little relevant recent activity aligned to its nominal product scope. Issuing bodies include county health departments, state HHS agencies, municipalities, and cooperative purchasing alliances serving multi-state and multi-jurisdictional public health systems.

The geographic spread spans Florida, Texas, Minnesota, and Oregon based on recent postings. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies budgeted at $700,000 and designated for its fire department, with a 5 percent bid discount available to certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities across multiple states. Bidders on these solicitations must typically provide unit costs, comply with E-Verify and drug-free workplace requirements, maintain specified insurance coverage, and deliver within defined timeframes with products meeting FDA standards and minimum shelf-life requirements.